Interleukin‐1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D‐HART2)
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Cardiology"
DOI: 10.1002/clc.22719
Abstract: Heart failure with preserved ejection fraction (HFpEF) now accounts for the majority of confirmed HF cases in the United States. However, there are no highly effective evidence‐based treatments currently available for these patients. Inflammation correlates… read more here.
Keywords: failure preserved; trial; heart; anakinra ... See more keywords
5233Interleukin-1 blockade with Anakinra in ST-segment elevation acute myocardial infarction: Results from the VCUART3 study
Sign Up to like & getrecommendations! Published in 2019 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehz746.0079
Abstract: ST-segment elevation myocardial infarction (STEMI) is associated with an intense inflammatory response that predicts an increased risk of death and heart failure (HF). In the current study we tested whether anakinra, a recombinant Interleukin-1 (IL-1)… read more here.
Keywords: segment elevation; myocardial infarction; anakinra; versus ... See more keywords
Steroid-sparing effect of anakinra in giant-cell arteritis: a case series with clinical, biological and iconographic long-term assessments.
Sign Up to like & getrecommendations! Published in 2021 at "Rheumatology"
DOI: 10.1093/rheumatology/keab280
Abstract: OBJECTIVES The treatment of giant cell arteritis (GCA) relies on corticosteroids but is burdened by a high rate of relapses and adverse effects. Anti-interleukin-6 treatments show a clear benefit with a significant steroid-sparing effect, but… read more here.
Keywords: giant cell; sparing effect; steroid sparing; cell arteritis ... See more keywords
Spondyloarthritis associated with familial Mediterranean fever: successful treatment with anakinra.
Sign Up to like & getrecommendations! Published in 2017 at "Rheumatology"
DOI: 10.1093/rheumatology/kew290
Abstract: SIR, FMF is an autosomal recessive, autoinflammatory disorder, with mutations in the MEFV gene. The clinical presentation is characterized by recurrent episodes of fever associated with abdominal, chest, joint and muscular pain [1, 2]. Colchicine… read more here.
Keywords: treatment; anakinra; colchicine; spondyloarthritis ... See more keywords
Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Preventive Cardiology"
DOI: 10.1177/2047487319879534
Abstract: Aims Novel therapies are needed for recurrent pericarditis, particularly when corticosteroid dependent and colchicine resistant. Based on limited data, interleukin-1 blockade with anakinra may be beneficial. The aim of this multicentre registry was to evaluate… read more here.
Keywords: dependent colchicine; corticosteroid dependent; anakinra; pericarditis ... See more keywords
Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0269065
Abstract: Objective We aimed to investigate whether anakinra, an interleukin-1receptor inhibitor, could improve outcome in moderate COVID-19 patients. Methods In this controlled, open-label trial, we enrolled adults with COVID-19 requiring oxygen. We randomly assigned patients to… read more here.
Keywords: safety; trial; osoc group; group ... See more keywords
Anakinra in hospitalized COVID-19 patients guided by baseline soluble urokinase plasminogen receptor plasma levels: A real world, retrospective cohort study
Sign Up to like & getrecommendations! Published in 2022 at "PLOS ONE"
DOI: 10.1371/journal.pone.0273202
Abstract: Background In patients with COVID-19 and baseline soluble urokinase plasminogen receptor plasma (suPAR) levels [≥] 6ng/mL, early administration of anakinra, a recombinant interleukin-1 receptor antagonist, may prevent disease progression and death. In case of suPAR… read more here.
Keywords: baseline; retrospective cohort; cohort study; anakinra ... See more keywords
Anakinra Pilot – a clinical trial to demonstrate safety, feasibility and pharmacokinetics of interleukin 1 receptor antagonist in preterm infants
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.1022104
Abstract: Background Bronchopulmonary dysplasia (BPD), its complication pulmonary hypertension (BPD-PH) and preterm brain and gut injury lead to significant morbidity and mortality in infants born extremely prematurely. There is extensive evidence that the pro-inflammatory cytokine interleukin… read more here.
Keywords: safety; anakinra pilot; trial; preterm infants ... See more keywords
Anakinra in Paediatric Rheumatology and Periodic Fever Clinics: Is the Higher Dose Safe?
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pediatrics"
DOI: 10.3389/fped.2022.823847
Abstract: Objective Anakinra has been increasingly used in off-label indications as well as dosing and mode of administration in a variety of inflammatory conditions. We aimed to review our clinical practice and compare treatment outcomes with… read more here.
Keywords: rheumatology; anakinra paediatric; rheumatology periodic; paediatric rheumatology ... See more keywords